A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.
about
Randomized controlled study of the safety and immunogenicity of pneumococcal vaccine formulations containing PhtD and detoxified pneumolysin with alum or adjuvant system AS02V in elderly adultsDevelopment of a novel preclinical model of pneumococcal pneumonia in nonhuman primates.Contributions to protection from Streptococcus pneumoniae infection using the monovalent recombinant protein vaccine candidates PcpA, PhtD, and PlyD1 in an infant murine model during challengeRole of pore-forming toxins in bacterial infectious diseases.Human antibodies to PhtD, PcpA, and Ply reduce adherence to human lung epithelial cells and murine nasopharyngeal colonization by Streptococcus pneumoniae.Insight into the evolution of the histidine triad protein (HTP) family in Streptococcus.Characterization of protective immune responses induced by pneumococcal surface protein A in fusion with pneumolysin derivatives.Expression of Streptococcus pneumoniae Virulence-Related Genes in the Nasopharynx of Healthy ChildrenVaccination against Streptococcus pneumoniae using truncated derivatives of polyhistidine triad protein DDiversity of Pneumolysin and Pneumococcal Histidine Triad Protein D of Streptococcus pneumoniae Isolated from Invasive Diseases in Korean Children.Passive protection of mice against Streptococcus pneumoniae challenge by naturally occurring and vaccine-induced human anti-PhtD antibodies.Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injuryNext generation protein based Streptococcus pneumoniae vaccinesSurface association of Pht proteins of Streptococcus pneumoniae.Reactogenicity, safety and immunogenicity of a protein-based pneumococcal vaccine in Gambian children aged 2-4 years: A phase II randomized study.A bivalent pneumococcal histidine triad protein D-choline-binding protein A vaccine elicits functional antibodies that passively protect mice from Streptococcus pneumoniae challenge.Safety, immunogenicity, and antibody persistence following an investigational Streptococcus pneumoniae and Haemophilus influenzae triple-protein vaccine in a phase 1 randomized controlled study in healthy adults.Preclinical evaluation of a chemically detoxified pneumolysin as pneumococcal vaccine antigen.Role of Pht proteins in attachment of Streptococcus pneumoniae to respiratory epithelial cellsUse of the 13-valent pneumococcal conjugate vaccine in infants and young children.Serotype-independent pneumococcal vaccines.Combination of adjuvants: the future of vaccine design.Current status and perspectives on protein-based pneumococcal vaccines.Streptococcus pneumoniae infection: a Canadian perspective.Malaria vaccine adjuvants: latest update and challenges in preclinical and clinical research.Nonhuman Primate Models of Respiratory Disease: Past, Present, and Future.Port d’Entrée for Respiratory Infections – Does the Influenza A Virus Pave the Way for Bacteria?Identification of SP1683 as a pneumococcal protein that is protective against nasopharyngeal colonization.
P2860
Q33601853-06C44BB2-EA11-4142-8192-FDFDECD2B4DCQ33799725-A46FD5CF-06BF-41AF-9034-75531F9DACE1Q34057765-EF1852C9-D5E1-4C83-91A4-A0B260947D57Q34346202-5DAEDDF4-DEFA-496B-87DC-C290A26B7DFDQ34595710-CDBB3F79-D210-4D6B-8039-8CD39718E8BEQ34635641-FB35BC4E-1DA0-4884-9506-AA455A3FF35BQ34637890-BBEF856B-56D8-46A8-9B1F-EA6A91E7BFC8Q34794776-A6787659-62BD-4E14-82E2-2F42921112DBQ35036855-D09B92F2-519A-4541-A409-ED0BD500681BQ35739683-8AD44FD5-4B5D-42DB-9F16-9D4F049C38E1Q35887448-237E27F9-0B35-446C-A501-37B0D6B6AB88Q36018158-7A682C91-F705-4DC5-B511-4C1F7EB6C76FQ37130191-D62289DB-D121-453B-8D43-8A41B119D899Q37264619-93CBD869-498B-4135-AEE2-B2721597629AQ37309298-7FB051A0-AF1D-410A-99F2-408933F46A97Q37473239-0E4AC25E-95EA-4DB7-A535-AC561BBC1DB9Q37544974-96327CFD-62A7-4D56-9045-1389C8C951B7Q37619137-474BA255-CE93-48A0-9C48-80A04CC0D5EEQ37713234-05FDBBB3-7779-41C1-B200-399BC0F64D3EQ37991405-75839CDF-886A-4B6C-AF0B-93797EDA628DQ38069943-FDD0748A-0CEC-48C7-BB9D-E2BEE5D7313EQ38124060-881EE37C-B25D-4DF8-A4B2-FC47BFF0400DQ38124921-6C14857D-B510-422F-8115-871278123620Q38131534-B0F14E15-C1B1-4B6A-9D04-36C8D37D6F6FQ40752357-61557E9B-33A3-41A8-AD86-00C01563DA25Q46432510-AC5F179A-B126-4753-818D-39B2682FEC9EQ47227733-E0096536-0E2B-4F5D-AB61-6C1B1198730FQ50199957-5501572B-3E2D-465A-8600-97FB524EA614
P2860
A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 May 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A protein-based pneumococcal v ...... with Streptococcus pneumoniae.
@en
A protein-based pneumococcal v ...... with Streptococcus pneumoniae.
@nl
type
label
A protein-based pneumococcal v ...... with Streptococcus pneumoniae.
@en
A protein-based pneumococcal v ...... with Streptococcus pneumoniae.
@nl
prefLabel
A protein-based pneumococcal v ...... with Streptococcus pneumoniae.
@en
A protein-based pneumococcal v ...... with Streptococcus pneumoniae.
@nl
P2093
P2860
P1433
P1476
A protein-based pneumococcal v ...... with Streptococcus pneumoniae.
@en
P2093
Dale Martin
Georges Carletti
Jan T Poolman
Lara Doyle
Mario T Philipp
Philippe Denoël
P2860
P304
P356
10.1016/J.VACCINE.2011.05.051
P407
P577
2011-05-30T00:00:00Z